Cargando…

Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review

BACKGROUND: Treatments for advanced melanoma are associated with different adverse events (AEs), which may be costly to manage. This study aimed to evaluate direct costs associated with managing treatment-related AEs for advanced melanoma through a systematic literature review. METHODS: Systematic s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Copley-Merriman, Catherine, Stevinson, Kendall, Liu, Frank Xiaoqing, Wang, Jingshu, Mauskopf, Josephine, Zimovetz, Evelina A., Chmielowski, Bartosz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081130/ https://www.ncbi.nlm.nih.gov/pubmed/30075584 http://dx.doi.org/10.1097/MD.0000000000011736

Ejemplares similares

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
por: Zimovetz, Evelina A., et al.
Publicado: (2017)

A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate
por: Zimovetz, Evelina A., et al.
Publicado: (2016)

The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review
por: Colosia, Ann D., et al.
Publicado: (2017)

Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions
por: Spinner, Daryl S, et al.
Publicado: (2013)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
por: Chmielowski, Bartosz
Publicado: (2013)

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
por: Cowey, C. Lance, et al.
Publicado: (2018)

Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review
por: Zimovetz, Evelina A, et al.
Publicado: (2012)

Direct medical costs of adverse events in Dutch hospitals
por: Hoonhout, Lilian HF, et al.
Publicado: (2009)

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
por: McArthur, Grant A., et al.
Publicado: (2017)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Management of Clitoral Melanoma Presenting as an Exophytic Clitoral Mass: A Case Report and Review of the Literature
por: Szlachta-McGinn, Alec, et al.
Publicado: (2021)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs
por: Anderson, Seri, et al.
Publicado: (2021)

Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study
por: Mordin, Margaret, et al.
Publicado: (2014)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

A Review of Immune-Mediated Adverse Events in Melanoma
por: Kennedy, Lucy Boyce, et al.
Publicado: (2019)

Complications and adverse events of plaque brachytherapy for ocular melanoma
por: Peddada, Krishi V., et al.
Publicado: (2019)

Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?
por: Mauskopf, Josephine, et al.
Publicado: (2021)

Comparing Cost-Effectiveness Results for a Vaccine Across Different Countries Worldwide: What Can We Learn?
por: Standaert, Baudouin, et al.
Publicado: (2014)

Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs
por: Mauskopf, Josephine A, et al.
Publicado: (2012)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review
por: Copley-Merriman, Catherine, et al.
Publicado: (2021)

Intra-articular Hyaluronic Acid for Osteoarthritis of the Knee in the United States: A Systematic Review of Economic Evaluations
por: Mordin, Margaret, et al.
Publicado: (2021)

Assessment of costs associated with adverse events in patients with cancer
por: Wong, William, et al.
Publicado: (2018)

Costs associated with adverse events among acute patients
por: Kjellberg, Jakob, et al.
Publicado: (2017)

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
por: de Filette, Jeroen, et al.
Publicado: (2016)

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
por: Schaefer, Anne, et al.
Publicado: (2020)

S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis
por: Hu, Qingqing, et al.
Publicado: (2023)

Malignant Melanoma: Direct Costs by Clinical and Pathological Profile
por: Buja, Alessandra, et al.
Publicado: (2022)

Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines
por: Mauskopf, Josephine, et al.
Publicado: (2014)

Hospital costs associated with adverse events in people with diabetes in the UK
por: Keng, Mi Jun, et al.
Publicado: (2022)

The psychological impact of adverse events on urology trainees
por: O’Meara, Sorcha, et al.
Publicado: (2022)

Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union
por: Clark, Marci J, et al.
Publicado: (2014)

High burden and unmet patient needs in chronic kidney disease
por: Braun, LeeAnn, et al.
Publicado: (2012)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events
por: Müller, Benjamin, et al.
Publicado: (2023)

CRAF R391W is a melanoma driver oncogene
por: Atefi, Mohammad, et al.
Publicado: (2016)

Management of adverse events of EUS-directed transgastric ERCP procedure
por: Ichkhanian, Yervant, et al.
Publicado: (2020)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
por: Jairath, Vipul, et al.
Publicado: (2022)

Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology
por: Bektas, Meryem, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3t2jmug9miihhvccalbjrvir0t